Indication and Important Safety Information | Full Prescribing Information
Resources for information and support

For more information about acromegaly and acromegaly support groups, visit the Web sites of the organizations below:

  • The Pituitary Network Association (PNA)
    PNA is an international non-profit organization for patients with acromegaly, their families, loved ones, and the physicians and health care providers who treat them. Learn more by visiting http://www.pituitary.org or http://www.acromegaly.org, or calling 1-805-499-9973.
  • The Pituitary Tumor Center of Massachusetts General Hospital
    Provided by Harvard Medical School, the Tumor Center Web site is available at http://pituitary.mgh.harvard.edu.
  • National Organization for Rare Disorders (NORD)
    NORD includes acromegaly in its rare-disease database and will email or fax a full report for a nominal fee. Visit http://rarediseases.org, or call 1-800-999-6673.
  • Acromegalysupport.org
    Recognizing that the pituitary disorder, acromegaly, is relatively unknown to the general public, Acromegalysupport.org has committed itself to establishing increased awareness through education and support. Visit http://www.acromegalysupport.org to learn more.

Glossary of terms

Find the meanings of any terms used in this Web site that you may not understand in the glossary.

Reimbursement for Somatuline Depot (lanreotide) Injection

Learn about insurance coverage, pharmacies that carry Somatuline® Depot (lanreotide) Injection, and the Reimbursement Hotline.

Watch a short video about injecting Somatuline Depot

See how easy it is to inject Somatuline® Depot (lanreotide) Injection. To view a brief video, click here.

Indication and Important Safety Information

Somatuline® Depot (lanreotide) Injection is a somatostatin analog indicated for the long-term treatment of patients with acromegaly who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy.

Lanreotide may reduce gallbladder motility and lead to gallstone formation. Periodic monitoring may be needed. Patients treated with Somatuline Depot may experience hypoglycemia or hyperglycemia. Glucose level monitoring is recommended and antidiabetic treatment adjusted accordingly. Lanreotide may lead to a decrease in heart rate. Use with caution in at-risk patients.

Patients with moderate and severe renal impairment or moderate and severe hepatic impairment should begin treatment with Somatuline Depot 60 mg.

There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human responses, Somatuline Depot should be used during pregnancy only if the potential benefit justifies risk to the fetus.

A decision should be made whether to discontinue nursing or discontinue the drug taking into account the importance of the drug to the mother.

Somatuline Depot may decrease the bioavailability of cyclosporine. Cyclosporine dose may need to be adjusted to maintain levels.

Patients receiving beta-blockers, calcium channel blockers, or other drugs that affect heart rate may need dose adjustments. Somatuline Depot may reduce the intestinal absorption of coadministered drugs. Caution should be used.

The most common adverse reactions (incidence >5%) are diarrhea (37%), cholelithiasis (20%), abdominal pain (19%), nausea (11%), injection-site reaction (9%), flatulence (7%), arthralgia (7%), and loose stools (6%).

For Full Prescribing Information, click here.